Adra, Nabil

Phase II Trial of Pembrolizumab in Patients with Platinum Refractory Germ-Cell Tumors: A Hoosier Cancer Research Network Study GU14-206

Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology

Testicular diseases and treatmentsCancer Immunotherapy and Biomarkers

Cited by 196

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology

Spratt, D. E., Srinivas, S., Adra, N., Ahmed, B., An, Y., Bitting, R., Chapin, B., Cheng, H. H., Cho, S. Y., D’Amico, A. V., et al. (2025) · Journal of the National Comprehensive Cancer Network

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 146

Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial)

Kuo, P. H., Morris, M. J., Hesterman, J., Kendi, A. T., Rahbar, K., Wei, X. X., Fang, B., Adra, N., Garje, R., Michalski, J. M., et al. (2024) · Radiology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 119

[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.

Kuo, P., Hesterman, J., Rahbar, K., Kendi, A. T., Wei, X. X., Fang, B., Adra, N., Armstrong, A. J., Garje, R., Michalski, J. M., et al. (2022) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 83

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Dorff, T., Horvath, L. G., Autio, K., Bernard-Tessier, A., Rettig, M. B., Machiels, J.-P., Bilen, M. A., Lolkema, M. P., Adra, N., Rottey, S., et al. (2024) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 76

Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

Chi, K. N., Armstrong, A. J., Krause, B. J., Herrmann, K., Rahbar, K., de Bono, J. S., Adra, N., Garje, R., Michalski, J. M., Kempel, M. M., et al. (2024) · European Urology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 37

1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Shen, J., Pachynski, R., Nordquist, L. T., Adra, N., Bilen, M. A., Aggarwal, R., Reichert, Z., Schweizer, M., Iravani, A., Aung, S., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 24

Phase II Trial of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Ashkar, R., Feldman, D. R., Adra, N., Zaid, M. A., Funt, S. A., Althouse, S. K., Perkins, S. M., Snow, C. I., Lazzara, K. M., Sego, L. M., et al. (2021) · Investigational New Drugs

Testicular diseases and treatmentsLymphoma Diagnosis and Treatment

Cited by 16

Relations of perceived injustice to psycho‐spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making

Secinti, E., Wu, W., Krueger, E. F., Hirsh, A. T., Torke, A. M., Hanna, N. H., Adra, N., Durm, G. A., Einhorn, L., Pili, R., et al. (2022) · Psycho-Oncology

Religion, Spirituality, and PsychologyCancer survivorship and care

Cited by 11